About: Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker
Creator	Li, Hong Zhou, Hong Chen, Xue Hu, Tinghua Ning, Qian Qiao, Libang Ren, Hui Shen, Liangrong Sun, Zhongmin
Source	Medline; PMC
abstract	In this study, we investigated the utility of pentraxin 3 (PTX-3) in bronchoalveolar lavage fluid (BALF) as lung cancer (LCa) diagnostic. A total of 89 LCa patients and 84 non-LCa patients who received bronchoscopy in the First Affiliated Hospital of Xi'an Jiaotong University from December 2014 to February 2015 were enrolled. LCa was subdivided according to pathological type (scale, gland, and small cell lung cancer). BALF samples were obtained during bronchoscopy and PTX-3 levels assayed by ELISA. t-tests, Mann-Whitney, and Kruskal-Wallis tests were performed for the comparison of PTX-3 levels between the different groups. Correlation analysis and receiver operating characteristic (ROC) analysis were used to analyze clinical data. The levels of PTX-3 increased in the LCa groups. PTX-3 levels were higher in the small cell lung cancer (SCLC) compared to non-small-cell lung cancer (NSCLC) groups. In LCa patients, obstructive pneumonia could upregulate the expression of PTX-3 in BALF. The area under the ROC curve of PTX-3 in BALF during LCa diagnosis, SCLC, and LCa with obstructive pneumonia was 0.949 (p ≤ 0.001), 0.672 (p < 0.05), and 0.838 (p < 0.01), respectively. In conclusion, PTX-3 in BALF has a potential value as an LCa biomarker, particularly in cases of SCLC and LCa with obstructive pneumonia.
has issue date	2020-06-10(xsd:dateTime)
bibo:doi	10.1155/2020/4652483
bibo:pmid	32587638
has license	cc-by
sha1sum (hex)	98744443dd4b7f3d0a505bdc9ad5267131e89f03
schema:url	https://doi.org/10.1155/2020/4652483
resource representing a document's title	Pentraxin 3 (PTX-3) Levels in Bronchoalveolar Lavage Fluid as a Lung Cancer Biomarker
has PubMed Central identifier	PMC7303750
has PubMed identifier	32587638
schema:publication	Dis Markers
resource representing a document's body	covid:98744443dd4b7f3d0a505bdc9ad5267131e89f03#body_text
is schema:about of	named entity 'BALF' named entity 'PTX' named entity 'bronchoscopy' named entity 'pathological' named entity 'LCa' named entity 'study' named entity 'PTX' named entity 'groups' named entity 'December' named entity 'total' named entity 'higher' named entity 'patients' named entity 'patients' named entity 'upregulate' named entity 'Hospital' named entity 'small cell lung cancer' named entity 'Lung Cancer' named entity 'bronchoscopy' named entity 'SCLC' named entity 'receiver operating characteristic' named entity 'SCLC' named entity 'small cell lung cancer' named entity 'pentraxin' named entity 'pneumonia' named entity 'BALF' named entity 'biomarker' named entity 'Correlation' named entity 'ROC' named entity 'SCLC' named entity 'Biomarker' named entity 'Bronchoalveolar Lavage' named entity 'SCLC' named entity 'kidney function' named entity 'immunocytes' named entity 'CYFRA 21-1' named entity 'bronchoalveolar lavage fluid' named entity 'BALF' named entity 'lung tissue' named entity 'lavage' named entity 'inflammatory' named entity 'anesthesia' named entity 'prognostic' named entity 'CEA' named entity 'standard error' named entity 'IL-1' named entity 'bronchoscopy' named entity 'informed consent' named entity 'PTX' named entity 'necrosis' named entity 'immune defenses' named entity 'correlation' named entity 'NSE' named entity 'centrifuged' named entity 'pulmonary arterial hypertension' named entity 'neutrophil' named entity '95% CI' named entity 'CEA' named entity 'bronchoscopy' named entity 'lung cancer' named entity 'lung cancer' named entity 'corticosteroids' named entity 'alveolar' named entity 'SCLC' named entity 'cytokeratin 19' named entity 'BALF' named entity 'lung cancer' named entity 'squamous cell carcinoma' named entity 'PTX' named entity 'PTX' named entity 'BALF' named entity 'lower respiratory tract' named entity 'bronchoalveolar lavage fluid' named entity 'BALF'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software